New Actions on Actionable Mutations in Lung Cancers-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

New Actions on Actionable Mutations in Lung Cancers

Published:2023-05-26 Issue:11 Volume:15 Page:2917
ISSN:2072-6694
Container-title:Cancers
language:en
Short-container-title:Cancers

Author:

Le Xiuning¹^ORCID,Elamin Yasir Y.¹,Zhang Jianjun¹²^ORCID

Affiliation:

1. Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

2. Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA

Abstract

Actionable mutations refer to DNA alterations that, if detected, would be expected to affect patients’ response to treatments [...]

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Link

https://www.mdpi.com/2072-6694/15/11/2917/pdf

Reference28 articles.

1. Defining actionable mutations for oncology therapeutic development;Carr;Nat. Rev. Cancer,2016

2. Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression;White;Clin. Lung Cancer,2021

3. Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC);Elamin;Clin. Lung Cancer,2019

4. Antiangiogenesis May Not Be a Universal Booster of EGFR Tyrosine Kinase Inhibitors;Wu;J. Thorac. Oncol.,2022

5. Molecular testing prior to first-line therapy in patients with stage IV nonsquamous non-small cell lung cancer (NSCLC): A survey of U.S. medical oncologists;Green;J. Clin. Oncol.,2014

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sex Difference in Disease-Related Adverse Events Post-Diagnosis of Lung Cancer Brain Metastases in Medicare Individuals ≥ 66 Years of Age;Cancers;2024-08-28

2. Clinical Benefit from Docetaxel +/− Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy;Cancers;2024-02-26

3. Real-World Outcomes of Crizotinib in ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer;Cancers;2024-01-26

4. Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancer;Clinical and Translational Oncology;2024-01-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3